No doubt this was a major setback for Idera & the tilsotolimod program, but to quote the legendary Yogi Berra, " it ain't over til it's over!" Having experienced similar events(setbacks) with previously owned biotechs, I know first hand the gut retching feeling felt yesterday afternoon by too many of us! But, there are other trials, Illuminate-206& the intradermal trial in the Netherlands, which could provide substantial new info that might very well validate tilso in other indications. There is still more data from illuminate-301 forthcoming. Have no idea about OS, but that still is the gold standard for cancer related trials. Dr.ElizabethTarka, MD, Chief Medical Officer, stated in a conference call over a year and half ago that the disease control rate correlates very closely with overall survival. What that number will be is anyone's guess, but until then it's still in play. This long term stockholder will remain in a wait and see mode until further notice.